

Human papillomavirus and genome instability: from productive infection to cancer

Bruna Prati, Bruna Marangoni, Enrique Boccardo*

Departamento de Microbiologia, Instituto de Ciencias Biomedicas, Universidade de Sao Paulo, Sao Paulo, SP, BR.

Prati B, Marangoni B, Boccardo E. Human papillomavirus and genome instability: from productive infection to cancer. Clinics. 2018;73(suppl 1):e539s

*Corresponding author. E-mail: eboccardo@usp.br

Infection with high oncogenic risk human papillomavirus types is the etiological factor of cervical cancer and a major cause of other epithelial malignancies, including vulvar, vaginal, anal, penile and head and neck carcinomas. These agents affect epithelial homeostasis through the expression of specific proteins that deregulate important cellular signaling pathways to achieve efficient viral replication. Among the major targets of viral proteins are components of the DNA damage detection and repair machinery. The activation of many of these cellular factors is critical to process viral genome replication intermediates and, consequently, to sustain faithful viral progeny production. In addition to the important role of cellular DNA repair machinery in the infective human papillomavirus cycle, alterations in the expression and activity of many of its components are observed in human papillomavirus-related tumors. Several studies from different laboratories have reported the impact of the expression of human papillomavirus oncogenes, mainly E6 and E7, on proteins in almost all the main cellular DNA repair mechanisms. This has direct consequences on cellular transformation since it causes the accumulation of point mutations, insertions and deletions of short nucleotide stretches, as well as numerical and structural chromosomal alterations characteristic of tumor cells. On the other hand, it is clear that human papillomavirus-transformed cells depend on the preservation of a basal cellular DNA repair activity level to maintain tumor cell viability. In this review, we summarize the data concerning the effect of human papillomavirus infection on DNA repair mechanisms. In addition, we discuss the potential of exploiting human papillomavirus-transformed cell dependency on DNA repair pathways as effective anti-tumoral therapies.

KEYWORDS: HPV; Genomic Instability; E6; E7; Cervical Cancer; Synthetic Lethality.

Human papillomaviruses and cancer

Human papillomaviruses (HPVs) are small, nonenveloped viruses with a genome composed of double-stranded circular DNA of approximately 8 kbp (1,2). HPVs belong to the *Papillomaviridae* family and, to date, over 200 different types have been identified and their genomes completely sequenced (1). The HPV genome can be divided in three functional regions. The upstream regulatory region (URR) or long control region (LCR) is a noncoding portion encompassing almost an eighth of the viral genome and is involved in the regulation of viral replication and transcription. In addition, there are two coding regions. The early (E) region harbors the E1, E2, E4, E5, E6 and E7 early genes that are critical for regulating viral genome replication, viral gene expression, immune evasion and genome persistence. The late (L) region

encodes the major and minor capsid proteins from the L1 and L2 genes, respectively. These viruses display a marked tropism for stratified epithelial tissues and are transmitted by direct contact with infected skin and mucosa. As such, HPV infections are associated with a variety of benign hyperproliferative conditions, such as common and genital warts.

Approximately 40 HPV types infect the mucosa and skin of the anogenital tract. These HPV types are further subclassified as low or high risk according to their association with the development of cervical carcinoma and its precursor lesions. Low-risk HPV types, such as HPV6 and HPV11, are associated with genital warts and low-grade cervical intra-epithelial neoplasia (CIN) (3,4). On the other hand, high-risk HPV types, for example, HPV16, HPV18, HPV31 and HPV45, are associated with the development of high-grade CIN and cervical cancer. In addition, they are associated with a significant proportion of vulvar, vaginal, anal, penile and head and neck carcinomas (5).

To establish a productive infection, HPVs have to reach cells from the basal layer of the epithelium. These are the only keratinocytes of the tissue that proliferate and express the DNA replication machinery. Therefore, they provide a permissive environment for initial viral genome replication. The virus can reach these cells through microwounds caused during sexual intercourse or at specific anatomical sites where the basal layer is readily accessible, such as the squamocolumnar junction (SCJ) of the cervix (6). Once in the cell

Copyright © 2018 CLINICS – This is an Open Access article distributed under the terms of the Creative Commons License (<http://creativecommons.org/licenses/by/4.0/>) which permits unrestricted use, distribution, and reproduction in any medium or format, provided the original work is properly cited.

No potential conflict of interest was reported.

Received for publication on December 27, 2017. **Accepted for publication on** May 16, 2018

Commemorative Edition: 10 years of ICESP

DOI: 10.6061/clinics/2018/e539s



nucleus, the HPV genome remains in the episomal state (100-500 copies/per cell) and replicates together with the cellular genome (7). The rest of the viral cycle, including vegetative genome amplification, structural protein expression, virion mounting and release, requires infected keratinocytes to migrate through the different layers of the epithelium and complete their differentiation program (8).

In high-grade CIN and HPV-associated tumors, viral DNA is frequently integrated into the host cell genome. Viral integration is an accidental event that usually disrupts the region where the E1 and E2 genes are located, leading to the loss of their expression. This constitutes a critical step in HPV-associated carcinogenesis since the loss of E2 leads to the upregulated expression of the main viral oncoproteins, namely, E6 and E7 (9). The sustained expression of E6 and E7 ensures the existence of a cellular milieu favorable for HPV replication in the suprabasal layers of the epithelium and is critical in the process of HPV-mediated cell transformation (see below) (10).

It is estimated that approximately 291 million women are infected by genital HPV types worldwide. Each year, nearly 500,000 new cases of cervical cancer are diagnosed and over 270,000 women die from this disease around the world. Importantly, most of the cases (~86%) and deaths (88%) occur in developing countries (1). Collectively, cervical cancer and the other HPV-associated malignancies represent 5.2% of all tumors affecting humans (11).

DNA damage repair pathways and the HPV cycle

DNA contains the essential information for the formation and function of an organism, and its preservation is critical for survival. DNA is a fairly stable macromolecule; however, it suffers constant attacks from extracellular and intracellular factors that jeopardize its integrity. These factors include chemical and physical agents, infectious agents, highly reactive metabolic byproducts, and replication errors (12). In fact, DNA damage is a common event in human cells. It is estimated that each human cell suffers approximately one million lesions in its DNA every day (13). Therefore, if DNA damage is not efficiently repaired, the integrity of the genome is compromised, causing the accumulation of mutations that ultimately may lead to premature aging, cancer development and death (14,15).

DNA repair is the process by which alterations in DNA are reverted. Usually, this involves the action of nucleases, helicases, ligases and DNA polymerases. Different specialized DNA repair mechanisms exist in which complex arrays of cellular proteins detect and repair different kinds of DNA lesions (16). These mechanisms include base excision repair (BER), nucleotide excision repair (NER), DNA mismatch repair (MMR), homologous recombination repair (HRR) and nonhomologous end joining (NHEJ). Hereditary or acquired defects in any of these pathways may lead to genome instability with severe consequences for the individual (17).

The DNA damage response (DDR) is composed of different signal transduction pathways that include damage sensors, signal transducers and effectors that act in a coordinated fashion to maintain genome integrity. Some DNA lesions activate specific sensors, such as the MRN complex (Mre11-RAD50-NSB1), replication protein A (RPA) or ATR-interacting protein (ATRIP), that trigger signaling pathways by the phosphorylation of apical protein kinases, such as ataxia telangiectasia mutated

(ATM), ataxia telangiectasia and Rad3 related (ATR) and DNA-dependent protein kinase (DNA-PK). Different types of DNA lesions activate different kinases (18,19). For instance, double-stranded DNA breaks may activate DNA-PK or ATM. On the other hand, single-stranded breaks preferentially activate ATR. The signaling cascade triggered by ATM and ATR then activates downstream kinases CHK2 (checkpoint kinase 2) and CHK1 (checkpoint kinase 1), respectively. However, the ATR-CHK1 and ATM-CHK2 pathways are not completely independent since they exhibit a high degree of redundancy and overlap. These pathways may regulate the phosphatase Cdc25 and activate the transcription factor p53, leading to cyclin-dependent kinase (CDK) inhibition and blocking cell cycle progression by the activation of specific checkpoints. Consequently, DNA damage effectors may mediate cell cycle arrest to allow DNA repair or, when the amount of damage is too high, induce cell death (14,17).

Many viruses, especially those with oncogenic properties, express proteins that affect the cell cycle and DNA damage repair regulatory pathways. Several studies have shown that during genome amplification, HPV proteins interact with different components of the cellular DNA repair machinery to activate or downregulate the expression or activity of factors of the ATM and ATR pathways. In 2009, Moody and coworkers showed that ATM activation is required for the productive genomic replication of HPV31 but not for episomal maintenance (20). On the other hand, it was observed that CHK1 inhibition causes an important reduction in the number of HPV episomes in differentiated cells (21). In addition, the knockdown of DNA topoisomerase 2-binding protein 1 (TopBP1), a protein that acts upstream of ATR, suppresses HPV31 replication (22). In line with these observations, it has been reported that E2 protein from HPV16 interacts with TopBP1 and that this interaction improves E2-mediated viral transcription and replication (23). Moreover, ATM and ATR kinases are constitutively activated in HPV-positive keratinocytes, and ATR/CHK1 blockade is associated with the downregulation of HPV productive replication and the reduced expression of late genes (22).

Importantly, many proteins from ATM and ATR pathways colocalize with HPV replication sites, further supporting the role of these factors in the HPV life cycle. Different studies have shown that E1 and E2 early proteins may activate the DDR, recruiting factors involved in DNA repair to process replication intermediates during viral genome amplification. Identified proteins at centers of HPV replication include 53BP1, ATRIP, OPBP1, p-ATM, p-H2AX, p-p53, ATR, CHK1, CHK2, PCNA, RPA, NBS1, BRCA1, RAD51, MRE11 and Ku70/80 (24-27) (Figure 1A). Collectively, these studies indicate that HPV may modulate different signaling pathways involved in the DDR to warrant effective viral transcription, faithful genome replication and, ultimately, the production of a large number of infective virions (10,28,29).

HPV oncoproteins pave the road to genome instability

The effect of specific HPV proteins on DNA repair pathways has been addressed by different groups. The HPV genome does not express proteins capable of mediating viral DNA replication and depends on the host cell machinery to achieve genome amplification. Therefore, it must induce the host cell to re-enter the S phase of the cell cycle to obtain access to the DNA replication machinery (30). This is accom-




Figure 1 - Interplay between HPV and cellular DNA repair machinery during infective viral cycle and virus-mediated cell transformation. A) During productive infection, HPV origin of replication (Ori) is triggered several times during the same cell cycle, leading to the “onion skin” type of DNA replication. To mediate genome amplification and process the viral genome replication intermediates, HPV activates and recruits several components of the DNA damage response (DDR), including 53BP1, ATRIP, OPbp1, p-ATM, p-H2AX, p-p53, ATR, CHK1, CHK2, PCNA, RPA, NBS1, BRCA1, RAD51, MRE11 and Ku70/80. HPV integration into the cellular genome may arise as a consequence of active DNA break repair. This event leads to E2 downregulation and increases the levels of E6 and E7 transcripts and proteins. B) In parallel to viral genome amplification, HPV oncoprotein expression increases the cell life span, induces alterations in chromosome segregation, prevents apoptosis and affects DNA repair, leading to the accumulation of alterations in cellular DNA. C) The presence of E2 protein either expressed from coexisting episomal viral genomes or derived from reinfection with the same or a different HPV type may trigger the replication of integrated HPV genomes, causing the rapid appearance of chromosome breaks and rearrangements, further contributing to malignant transformation. For references, see the main text.

plished by the action of viral proteins, mainly E6 and E7, on cellular factors involved in cell cycle regulation. E6 and E7 are the major HPV transforming proteins, and their sustained expression is required to maintain the oncogenic properties of HPV-transformed cells in most scenarios (31-33). These proteins collaborate to immortalize primary cells and can independently abrogate the mitotic checkpoint and p53-mediated cell cycle arrest in response to DNA damage (34,35).

Among the main targets of E6 is the tumor suppressor protein p53. E6 forms a ternary complex with E6-associated protein (E6AP) and p53, altering p53's functional capacity and inducing the degradation of this cellular protein by the ubiquitin-mediated proteolysis pathway (36-38). In addition, E6 from HPV16 binds the transcriptional coactivator CREB-binding protein/p300 (CBP/p300) and downregulates its ability to activate p53-responsive elements in the promoters of several p53-regulated genes (39). E6 protein also upregulates the expression of the catalytic subunit of telomerase (hTERT) in primary cells and delays cell senescence (40). Moreover, E6 targets other cellular factors, including those regulating cell polarity (PDZ proteins), apoptosis and cell differentiation (40,41). Similarly, E7 from high-risk HPV types binds and induces the degradation of members of the retinoblastoma (pRb) tumor suppressor proteins pRb1^{P110}, p107 and p130 (pRb2). This interrupts the interaction of pRb

proteins with members of the E2F transcription factor family. Once free from inhibition, E2F activates the transcription of several genes involved in S phase induction and progression, including cyclins A and E (42,43). E7 also promotes cell cycle progression by downregulating the activity of cyclin-dependent kinase inhibitors (CKIs) p21 and p27 (44,45). In addition, E7 of high-risk HPV16 and HPV31 interact with histone deacetylases 1 and 2 (HDAC1 and HDAC2), affecting the gene expression pattern of infected cells. Together, these data show that E6 and E7 affect the proliferation and differentiation of human keratinocytes by extending the lifespan of these cells (46,47).

Due to their impact on different cellular pathways, HPV oncoproteins may also promote the accumulation of genomic alterations that contribute to malignant transformation (48-54). For instance, Song and coworkers (55) demonstrated that mouse cells expressing E6 and E7 from high-risk HPV types continue to replicate DNA even in the presence of lesions induced by ionizing radiation (IR) and accumulate large numbers of alterations in the molecule. Similarly, HPV16 E7 expression is associated with the persistence of γ H2AX and Rad51 foci upon the exposure of head and neck cancer cells to IR (56). Importantly, the expression of high-risk E6 and E7 proteins has been associated with the induction of DNA breaks and a high frequency of foreign DNA integration into host cells (35,57).



Several studies have shown that ATM and ATR pathways are targeted by HPV oncoproteins. For instance, Banerjee et al. (30) observed that the oncoprotein E7 from HPV18 induces increased levels of phosphorylated ATM and the downstream kinases CHK1, CHK2, and JNKs (c-Jun N-terminal kinases). It was also reported that E7 from HPV31 binds ATM, inducing its phosphorylation and activating CHK2 (20). Another study showed that E7 from HPV16 induces the degradation of claspain, a protein from the ATR-CHK1 pathway, attenuating the DNA damage checkpoint (58). In addition, the results from recent studies support the involvement of HPV in skin cancer. In this context, it was observed that the protein E6 from HPV5 and HPV8, two important cutaneous HPV types, reduces ATM levels and downregulates the p300/ATR signaling axis, leading to the persistence of DNA lesions induced by UVB light (10,59). Finally, it was observed that E6 and E7 from HPV16 interact with breast cancer-associated protein 1 (BRCA1), inactivating its function in the repair of double-stranded DNA breaks (60).

Other alterations in DNA repair systems associated with HPVs have been described by different groups. One report has shown that oral keratinocytes immortalized with HPV16 exhibit deficiencies in the NER system and, consequently, are unable to remove cyclobutane pyrimidine dimers (CPDs) induced by UV light (61). A similar observation was made in fibroblasts expressing E7 from HPV16. These cells show defective NER activity and display a marked delay in the removal of CPDs induced by UVB light (62). Recently, it was observed that cells derived from squamous carcinoma of the head and neck positive for HPV are more sensitive to radiotherapy than HPV-negative cell lines due to a defect in BER in the the former cells (63). This finding is also in agreement with observations showing that E7 delays the repair of DNA lesions induced by IR in culture systems and laboratory animal models (56).

The oncoprotein E6 also targets DNA repair pathways. For instance, epithelial mammary cells expressing this protein from HPV16 exhibit a reduced capacity for removing thymine dimers after exposure to UV light (64,65). In addition, oral fibroblasts expressing E6 from HPV16 exhibit an impaired ability to repair double-stranded breaks by NHEJ. Interestingly, E6 achieves this effect via either p53-dependent or p53-independent pathways (66). Moreover, it has been described that E6 mediates O⁶-methylguanine DNA methyltransferase (MGMT) degradation via the ubiquitin/proteasome pathway in a process that requires the interaction of E6 with E6AP. The action of MGMT, which is impaired by E6, protects cells and tissues against the effects of alkylating agents (67). Finally, it was reported that E6 from different HPV types targets X-ray repair cross-complementing protein 1 (XRCC1) and inhibits its ability to repair DNA lesions (68).

These observations show that HPV infection may increase the frequency of DNA alterations in the host cell and delay the removal of these alterations by targeting DNA repair pathways. In addition, by impairing cell cycle checkpoints and apoptosis, HPV oncoproteins cause sustained proliferation while preventing cell death. Collectively, these effects may lead to cellular alterations that give rise to precursor lesions with a tendency for malignant progression.

HPV-mediated genome instability and cancer

During tumor evolution, cells acquire genetic alterations that may upregulate the expression of proto-oncogenes or

induce gain-of-function mutations in these genes. In addition, mutations, deletions and alterations in the methylation pattern of promoter sequences may downregulate the activity of tumor suppressor genes. Cells harboring these alterations may have proliferative advantages and acquire other phenotypical alterations, such as the capacity to invade other tissues and organs (69). Genome instability is a defining phenotype of most malignant tumors that comprises numerical and structural chromosomal abnormalities, as well as microdeletions, small insertions, the duplication of short nucleotide stretches and the accumulation of point mutations. Alterations in the sequences or expression level of proteins involved in DNA damage repair may result in the accumulation of genetic modifications important for cancer development. Normal cells exhibit an impressive array of mechanisms to detect and repair DNA defects. However, many of these mechanisms are altered in tumors cells (70,71). Although HPV activates several DNA repair pathways to assist its genome replication, as described above, HPV-induced tumors exhibit a high degree of genome instability. This fact seems to be critical for HPV-mediated carcinogenesis and suggests that DNA repair is attenuated during the steps leading from cellular transformation to cancer onset (7,35).

In hereditary cancers, mutations transmitted from progenitors predispose the host to the development of certain types of tumors and/or increase their sensitivity to carcinogens. This process may involve alterations in components of different DNA repair pathways. Several studies have suggested that mutations in this group of genes may act as cofactors in the establishment and progression of HPV-associated tumors. For instance, patients with Fanconi anemia (FA) or individuals carrying mutations in the breast cancer-associated (BRCA) gene exhibit a higher risk of developing HPV-associated cancerous lesions (72). In fact, the expression of HPV16 E7 in FA-deficient fibroblasts is associated with an increased number of chromosome aberrations (73). Moreover, K14E7/FancD2(-/-) mice exhibit a significantly higher incidence of head and neck squamous cell carcinoma than animals expressing K14E7 on a normal FancD2 background (+ / +) (74). Using a similar approach, it was observed in FA-deficient mice that cervical tumors persisted even in the absence of HPV16 E7 expression, supporting the notion that FA-deficient tumors may escape from their dependency on the viral oncogene (32). Upregulation of the FA pathway is a frequent event in cervical SCC. *In vitro* data indicate that the activation of this pathway is mediated by E7 and is characterized by the formation of large FANCD2 foci and the recruitment of FANCD2 and FANCD1/BRCA2 to chromatin (73). These observations suggest that FA pathway activation plays a role in the HPV cycle. The malfunction of this pathway may lead to the accumulation of HPV-mediated genomic alterations and the promotion of tumor development in FA patients. Of clinical relevance, in this context, where FA facilitates the accumulation of mutations, sustained viral oncogene expression may no longer be required to maintain the transformed phenotype (32).

Alterations in the expression of genes involved in DNA damage sensing and repair are readily detected in HPV-associated cancers and precursor lesions. A study that analyzed the expression of genes involved in BER in 50 invasive cervical cancer patients and 40 squamous intraepithelial lesions (SILs) showed that the expression of *XRCC1*, *ERCC2*, *ERCC4* and *ERCC1*, at both the mRNA and protein levels,



was downregulated in tumors and precursor lesions compared to samples from control subjects (75). Recently, Seiwert et al. (76) sequenced 617 cancer-associated genes in 120 matched head and neck squamous cell carcinoma/normal samples, of which 42.5% were positive for HPV DNA. They observed that HPV-positive tumors showed 5.8% of DNA repair gene aberrations (including 7.8% of BRCA1/2 mutations). In a study conducted in our laboratory, we compared the expression pattern of 135 genes involved in DNA damage repair/signaling between normal human keratinocytes and cervical cancer-derived cell lines and observed that the mRNA levels of 18 genes are altered in HPV-transformed cell lines (77).

Genome instability, in the context of HPV infection, may arise through different molecular pathways. A clear example of this is represented by the results of a study conducted by Kadaja et al. (25). The authors reported that the ectopic expression of HPV18 E1 and E2 triggers HPV replication from viral-integrated HPV genomes in SiHa and HeLa cells, leading to the accumulation of chromosome defects. Different from the cellular origin of replication, which is activated once per cell cycle, the viral origin of replication can be triggered several times during the same cell cycle, leading to the “onion skin” type of DNA replication. This process generates replication intermediates that stress the DNA molecules, leading to double- or single-stranded breaks and the recruitment of DNA repair machinery that ligates loose DNA ends and promotes chromosomal rearrangement. These observations raise the disturbing possibility that the coexistence of integrated and episomal HPV genomes in the same cell may induce chromosome aberrations arising from the integrated viral DNA. Moreover, the *de novo* HPV infection of cells harboring integrated DNA genomes may also endanger the cellular genome integrity and favor cell transformation (Figure 1C).

Chronic inflammation also plays a major role in cancer biology (69). This is also true for tumors associated with HPV infection (78). For instance, cells harboring HPV16 genomes exhibit increased levels of nitric oxide (NO), which triggers inflammation and promotes DNA breaks (79). In addition, extracellular factors, mainly inflammatory mediators, may affect HPV infection outcome. For instance, it has been observed that interferon β may induce the elimination of HPV16 episomes from naturally infected cervical keratinocytes by selecting cells with integrated viral genomes (80). In addition, interferon may induce HPV genome integration (81). These observations suggest that chronic inflammation may potentiate viral persistence and, consequently, lesion establishment and progression (82). Importantly, these findings indicate that HPV therapies should be evaluated for the potential selection of cells with integrated genomes and increased proliferative potential.

As previously stated, HPV oncogenes E6 and E7 play a critical role in HPV-mediated carcinogenesis by affecting major cellular processes. The consequences of HPV oncoprotein actions are reflected on cellular genome homeostasis. For instance, inhibition of the postmitotic checkpoint by high-risk HPV E6 and E7 is associated with the induction of polyploidy in human keratinocytes (83-85). It was also observed that HPV16 oncoprotein expression induce supernumerary centrosomes and multipolar mitotic spindles that may lead to aneuploidy (49). In addition, an independent study showed that E6 oncoprotein causes centrosome accumulation, while HPV16 E7 interferes with the centrosome

duplication cycle (86). Interestingly, while E7 from HPV16 may induce the delocalization of dynein from mitotic spindles, this has not been correlated with mitotic defects (87) (Figure 1B).

Alterations in the regulation of the cell cycle and the inhibition of proapoptotic factors are important underlying events in HPV-mediated genome instability. As expected, genomic instability is an early event during HPV infection that precedes viral integration, the development of associated lesions and their eventual progression to cancer (88-90). Genomic instability is crucial in the appearance of aneuploid cells and lesion progression (88). This is highlighted by the fact that highly polyploid as well as aneuploid cells are mainly detected in high-grade cervical lesions (91). Of note, most of the alterations described are restricted to cells infected with high-risk HPV types and are not detected upon infection with low-risk types (92). Studies conducted using clinical samples have shown that cervical tumors exhibit a plethora of chromosomal alterations, including gains in 1, 3q, 5p, 6p, 7, 8q, 9q, 16q, and 20 and losses in 2q, 3p, 4q, 6q, 11q, 13q, 16, and 17 (93-98). Finally, genomic alterations associated with HPV infection have also been observed in tumors from different anatomical locations, including oral, anal, laryngeal and head and neck neoplasias (76,99-101).

Genome instability is probably not a consequence of HPV-mediated malignant transformation. However, it may favor the acquisition of genetic alterations that confer growing advantages to cells expressing viral oncogenes. In addition, the underlying mutator phenotype may allow transformed cells to adapt rapidly to the harsh conditions of the tumor microenvironment, contributing to tumor onset and progression.

HPV-associated disease treatment: can we target DNA repair systems?

The data discussed above further support the established notion that the main mechanism by which HPV induces cell transformation is the targeting of p53 and pRb by E6 and E7, respectively (43,102-104). Therefore, it is assumed that the downregulation of these tumor suppressor proteins by E6 and E7 mimics the effect of inactivating mutations observed in p53 and pRb in tumors not associated with HPV infection. Consequently, it is believed that HPV-positive cancers, including anogenital, oropharyngeal tract and anal canal tumors, are less likely to present p53 and pRb mutations (105,106). Conversely, different studies have shown that HPV-transformed cells retain the ability to respond to genotoxic stress by inducing a p53-mediated response. Therefore, p53 downregulation as a consequence of HPV oncogene action is not functionally equivalent to p53 inactivation by mutation (107-109). This may be at least one of the underlying molecular mechanisms explaining why the presence of HPV is associated with a better response to therapy and constitutes a positive prognostic factor for patients with oropharyngeal tumors (110).

However, the implementation of new therapeutic strategies to treat HPV-associated tumors is still required. In this context, the dependence of HPV-transformed cells on cellular DNA repair machinery may constitute a suitable target for intervention. In fact, inhibitors of selected molecules involved in specific cellular pathways have been applied for the treatment of cervical cancer in clinical trials (111,112).



In addition, several examples of synthetic lethality involving genes from DNA damage repair systems and tumor suppressor-regulated pathways have been described and suggested as potential targets for cancer therapy (113).

The first case of synthetic lethality involving genes associated with DNA damage repair was with poly(ADP-ribose) polymerase (PARP) and breast and ovarian cancer susceptibility genes BRCA1 and BRCA2 (114,115). PARP is a family of proteins involved in several cellular processes, including DNA repair and the maintenance of genome stability. PARP1, the most studied member of the family, is rapidly recruited to nicks and double-stranded breaks in cellular DNA, where it gathers components of the DNA repair machinery and promotes the removal of lesions (116). In fact, cells with alterations in different DNA damage repair pathways exhibit increased susceptibility to the loss of PARP activity. As expected, PARP inhibitors (iPARPs) prevent DNA damage repair and are used in cancer therapy, particularly in tumors with germline or somatic mutations in BRCA1/2 (117). The administration of iPARPs promotes cell death by downregulating BER and promoting the accumulation of DNA defects in the cell (116,118-121). Additionally, by preventing DNA repair, PARP inhibition increases the sensitivity of cells to chemotherapeutic agents that promote DNA lesions (122).

E6 and E7 form high-risk HPV types are pleotropic proteins that target an increasing list of cellular factors affecting their expression and function. As such, HPV-transformed cells exhibit major alterations in important signaling pathways and cellular processes, including several DNA damage repair mechanisms. This fact has consequences of clinical relevance. For instance, patients harboring HPV-associated head and neck squamous cell carcinoma (HNSCC) have significantly improved survival compared with patients affected by HPV-negative tumors. Although the molecular mechanisms underlying this difference are not completely understood, it is accepted that impaired DNA repair abilities, probably due to HPV oncoproteins action, play a major role (110,123). In fact, HPV-positive HNSCC-derived cell lines accumulate more double-stranded DNA breaks than HPV-negative counterparts and exhibit higher radiosensitivity (63,124). In conclusion, HPV-transformed cells exhibit major defects in DNA repair. Nevertheless, we anticipate that HPV-transformed cells depend on the preservation of a basal level of DNA repair activity mediated by cellular machinery to maintain the minimal genomic stability needed for tumor cell viability. Therefore, a great effort should be directed toward identification of the molecular pathways necessary for the survival HPV-driven tumor cells. This will certainly contribute to the development of more efficient antitumor therapies.

■ ACKNOWLEDGMENTS

This research was supported by grants from the FAPESP (2010/20002-0) and CNPq (480552/2011-8), as well as a fellowship awarded to BP (CNPq 573799/2008-3; CAPES 1524553).

■ AUTHOR CONTRIBUTIONS

Prati B prepared the text describing the effect of HPV on DNA repair machinery. Marangoni B prepared the text describing HPV-associated disease treatment strategies. Boccardo E prepared, revised and corrected all the text.

■ REFERENCES

1. International Agency for Research on Cancer. Human Papillomaviruses, vol. 90; 2007 [Internet]. IARC Monographs on the evaluation of carcinogenic risks to humans. Available from: <http://monographs.iarc.fr/ENG/Monographs/vol90/mono90-6.pdf%5Cnhttp://monographs.iarc.fr/ENG/Monographs/vol100B/mono100B-11.pdf>
2. Bernard HU, Burk RD, Chen Z, van Doorslaer K, zur Hausen H, de Villiers EM. Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. *Virology*. 2010;401(1):70-9, <http://dx.doi.org/10.1016/j.virol.2010.02.002>.
3. zur Hausen H. Papillomaviruses in the causation of human cancers - a brief historical account. *Virology*. 2009;384(2):260-5, <http://dx.doi.org/10.1016/j.virol.2008.11.046>.
4. Bosch FX, de Sanjose S, Castellsague X. HPV and genital cancer: the essential epidemiology. In: *Vaccines for the Prevention of Cervical Cancer* [Internet]. Oxford University Press; 2008. Available from: <http://oxfordmedicine.com/view/10.1093/med/9780199543458.001.0001/med-9780199543458-chapter-4>
5. Parkin DM, Bray F. Chapter 2: The burden of HPV-related cancers. *Vaccine*. 2006;24 Suppl 3: S3/11-25, <http://dx.doi.org/10.1016/j.vaccine.2006.05.111>.
6. Herfs M, Yamamoto Y, Laury A, Wang X, Nucci MR, McLaughlin-Drubin ME, et al. A discrete population of squamocolumnar junction cells implicated in the pathogenesis of cervical cancer. *Proc Natl Acad Sci U S A*. 2012;109(26): 10516-21, <http://dx.doi.org/10.1073/pnas.1202684109>.
7. Moody CA, Laimins LA. Human papillomavirus oncoproteins: pathways to transformation. *Nat Rev Cancer*. 2010;10(8):550-60, <http://dx.doi.org/10.1038/nrc2886>.
8. Doorbar J. The papillomavirus life cycle. *J Clin Virol*. 2005;32 Suppl 1: S7-15, <http://dx.doi.org/10.1016/j.jcv.2004.12.006>.
9. Münger K, Baldwin A, Edwards KM, Hayakawa H, Nguyen CL, Owens M, et al. Mechanisms of human papillomavirus-induced oncogenesis. *J Virol*. 2004;78(21):11451-60, <http://dx.doi.org/10.1128/JVI.78.21.11451-11460.2004>.
10. Wallace NA, Gasior SL, Faber ZJ, Howie HL, Deininger PL, Galloway DA. HPV 5 and 8 E6 expression reduces ATM protein levels and attenuates LINE-1 retrotransposition. *Virology*. 2013;443(1):69-79, <http://dx.doi.org/10.1016/j.virol.2013.04.022>.
11. Tota JE, Chevarie-Davis M, Richardson LA, Devries M, Franco EL. Epidemiology and burden of HPV infection and related diseases: implications for prevention strategies. *Prev Med*. 2011;53 Suppl 1: S12-21, <http://dx.doi.org/10.1016/j.ypmed.2011.08.017>.
12. Lindahl T. Instability and decay of the primary structure of DNA. *Nature*. 1993;362(6422):709-15, <http://dx.doi.org/10.1038/362709a0>.
13. Branzel D, Foiani M. Regulation of DNA repair throughout the cell cycle. *Nat Rev Mol Cell Biol*. 2008;9(4):297-308, <http://dx.doi.org/10.1038/nrm2351>.
14. Sulli G, Di Micco R, d'Adda di Fagagna F. Crosstalk between chromatin state and DNA damage response in cellular senescence and cancer. *Nat Rev Cancer*. 2012;12(10):709-20, <http://dx.doi.org/10.1038/nrc3344>.
15. Sancar A, Lindsey-Boltz LA, Unsal-Kaçmaz K, Linn S. Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. *Annu Rev Biochem*. 2004;73:39-85, <http://dx.doi.org/10.1146/annurev.biochem.73.011303.073723>.
16. Zhou BB, Elledge SJ. The DNA damage response: putting checkpoints in perspective. *Nature*. 2000;408(6811):433-9, <http://dx.doi.org/10.1038/35044005>.
17. Yang J, Yu Y, Hamrick HE, Duerksen-Hughes PJ. ATM, ATR and DNA-PK: initiators of the cellular genotoxic stress responses. *Carcinogenesis*. 2003;24(10):1571-80, <http://dx.doi.org/10.1093/carcin/bgg137>.
18. Abraham RT. Cell cycle checkpoint signaling through the ATM and ATR kinases. *Genes Dev*. 2001;15(17):2177-96, <http://dx.doi.org/10.1101/gad.914401>.
19. Lowndes NF, Murguia JR. Sensing and responding to DNA damage. *Curr Opin Genet Dev*. 2000;10(1):17-25, [http://dx.doi.org/10.1016/S0959-437X\(99\)00050-7](http://dx.doi.org/10.1016/S0959-437X(99)00050-7).
20. Moody CA, Laimins LA. Human papillomaviruses activate the ATM DNA damage pathway for viral genome amplification upon differentiation. *PLoS Pathog*. 2009;5(10):e1000605, <http://dx.doi.org/10.1371/journal.ppat.1000605>.
21. Edwards TG, Helmus MJ, Koeller K, Bashkin JK, Fisher C. Human papillomavirus episome stability is reduced by aphidicolin and controlled by DNA damage response pathways. *J Virol*. 2013;87(7):3979-89, <http://dx.doi.org/10.1128/JVI.03473-12>.
22. Hong S, Cheng S, Iovane A, Laimins LA. STAT-5 Regulates Transcription of the Topoisomerase II β -Binding Protein 1 (TopBP1) Gene To Activate the ATR Pathway and Promote Human Papillomavirus Replication. *MBio*. 2015;6(6):e02006-15, <http://dx.doi.org/10.1128/mBio.02006-15>.
23. Boner W, Taylor ER, Tsirimonaki E, Yamane K, Campo MS, Morgan IM. A Functional interaction between the human papillomavirus 16 transcription/replication factor E2 and the DNA damage response protein



- TopBP1. *J Biol Chem.* 2002;277(25):22297-303, <http://dx.doi.org/10.1074/jbc.M202163200>.
24. Gillespie KA, Mehta KP, Laimins LA, Moody CA. Human papillomaviruses recruit cellular DNA repair and homologous recombination factors to viral replication centers. *J Virol.* 2012;86(17):9520-6, <http://dx.doi.org/10.1128/JVI.00247-12>.
 25. Kadaja M, Isok-Paas H, Laos T, Ustav E, Ustav M. Mechanism of genomic instability in cells infected with the high-risk human papillomaviruses. *PLoS Pathog.* 2009;5(4):e1000397, <http://dx.doi.org/10.1371/journal.ppat.1000397>.
 26. Reinson T, Toots M, Kadaja M, Pipitch R, Allik M, Ustav E, et al. Engagement of the ATR-dependent DNA damage response at the human papillomavirus 18 replication centers during the initial amplification. *J Virol.* 2013;87(2):951-64, <http://dx.doi.org/10.1128/JVI.01943-12>.
 27. Sakakibara N, Mitra R, McBride AA. The papillomavirus E1 helicase activates a cellular DNA damage response in viral replication foci. *J Virol.* 2011;85(17): 8981-95, <http://dx.doi.org/10.1128/JVI.00541-11>.
 28. Swindle CS, Zou N, Van Tine BA, Shaw GM, Engler JA, Chow LT. Human papillomavirus DNA replication compartments in a transient DNA replication system. *J Virol.* 1999;73(2):1001-9.
 29. Gillespie KA, Mehta KP, Laimins LA, Moody CA. Human papillomaviruses recruit cellular DNA repair and homologous recombination factors to viral replication centers. *J Virol.* 2012;86(17):9520-6, <http://dx.doi.org/10.1128/JVI.00247-12>.
 30. Banerjee NS, Wang HK, Broker TR, Chow LT. Human papillomavirus (HPV) E7 induces prolonged G2 following S phase reentry in differentiated human keratinocytes. *J Biol Chem.* 2011;286(17):15473-82, <http://dx.doi.org/10.1074/jbc.M110.197574>.
 31. Goodwin EC, DiMaio D. Repression of human papillomavirus oncogenes in HeLa cervical carcinoma cells causes the orderly reactivation of dormant tumor suppressor pathways. *Proc Natl Acad Sci U S A.* 2000; 97(23):12513-8, <http://dx.doi.org/10.1073/pnas.97.23.12513>.
 32. Park S, Park JW, Pitot HC, Lambert PF. Loss of Dependence on Continued Expression of the Human Papillomavirus 16 E7 Oncogene in Cervical Cancers and Precancerous Lesions Arising in Fanconi Anemia Pathway-Deficient Mice. *MBio.* 2016;7(3): e00628-16, <http://dx.doi.org/10.1128/mBio.00628-16>.
 33. Hoppe-Seyler K, Bossler F, Lohrey C, Bulkescher J, Rösl F, Jansen L, et al. Induction of dormancy in hypoxic human papillomavirus-positive cancer cells. *Proc Natl Acad Sci U S A.* 2017;114(6):E990-E8, <http://dx.doi.org/10.1073/pnas.1615758114>.
 34. Halbert CL, Demers GW, Galloway DA. The E6 and E7 genes of human papillomavirus type 6 have weak immortalizing activity in human epithelial cells. *J Virol.* 1992;66(4):2125-34.
 35. Duensing S, Münger K. The human papillomavirus type 16 E6 and E7 oncoproteins independently induce numerical and structural chromosome instability. *Cancer Res.* 2002;62(23):7075-82.
 36. Crook T, Tidy JA, Vousden KH. Degradation of p53 can be targeted by HPV E6 sequences distinct from those required for p53 binding and trans-activation. *Cell.* 1991;67(3):547-56, [http://dx.doi.org/10.1016/0092-8674\(91\)90529-8](http://dx.doi.org/10.1016/0092-8674(91)90529-8).
 37. Lechner MS, Mack DH, Finicle AB, Crook T, Vousden KH, Laimins LA. Human papillomavirus E6 proteins bind p53 in vivo and abrogate p53-mediated repression of transcription. *EMBO J.* 1992;11(8):3045-52, <http://dx.doi.org/10.1002/j.1460-2075.1992.tb05375.x>.
 38. Scheffner M, Huibregtse JM, Vierstra RD, Howley PM. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. *Cell.* 1993;75(3):495-505, [http://dx.doi.org/10.1016/0092-8674\(93\)90384-3](http://dx.doi.org/10.1016/0092-8674(93)90384-3).
 39. Patel D, Huang SM, Baglia LA, McCance DJ. The E6 protein of human papillomavirus type 16 binds to and inhibits co-activation by CBP and p300. *EMBO J.* 1999;18(18):5061-72, <http://dx.doi.org/10.1093/emboj/18.18.5061>.
 40. Klingelhutz AJ, Foster SA, McDougall JK. Telomerase activation by the E6 gene product of human papillomavirus type 16. *Nature.* 1996;380(6569):79-82, <http://dx.doi.org/10.1038/380079a0>.
 41. Pim D, Banks L. Interaction of viral oncoproteins with cellular target molecules: infection with high-risk vs low-risk human papillomaviruses. *APMIS.* 2010;118(6-7):471-93, <http://dx.doi.org/10.1111/j.1600-0463.2010.02618.x>.
 42. Barbosa MS, Edmonds C, Fisher C, Schiller JT, Lowy DR, Vousden KH. The region of the HPV E7 oncoprotein homologous to adenovirus E1a and Sv40 large T antigen contains separate domains for Rb binding and casein kinase II phosphorylation. *EMBO J.* 1990;9(1):153-60, <http://dx.doi.org/10.1002/j.1460-2075.1990.tb08091.x>.
 43. Dyson N, Howley PM, Münger K, Harlow E. The human papillomavirus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. *Science.* 1989;243(4893):934-7, <http://dx.doi.org/10.1126/science.2537532>.
 44. Helt AM, Galloway DA. Destabilization of the retinoblastoma tumor suppressor by human papillomavirus type 16 E7 is not sufficient to overcome cell cycle arrest in human keratinocytes. *J Virol.* 2001;75(15): 6737-47, <http://dx.doi.org/10.1128/JVI.75.15.6737-6747.2001>.
 45. Cho NH, Kim YT, Kim JW. Alteration of cell cycle in cervical tumor associated with human papillomavirus: cyclin-dependent kinase inhibitors. *Yonsei Med J.* 2002;43(6):722-8, <http://dx.doi.org/10.3349/ymj.2002.43.6.722>.
 46. Brehm A, Nielsen SJ, Miska EA, McCance DJ, Reid JL, Bannister AJ, et al. The E7 oncoprotein associates with Mi2 and histone deacetylase activity to promote cell growth. *EMBO J.* 1999;18(9):2449-58, <http://dx.doi.org/10.1093/emboj/18.9.2449>.
 47. Longworth MS, Laimins LA. The binding of histone deacetylases and the integrity of zinc finger-like motifs of the E7 protein are essential for the life cycle of human papillomavirus type 31. *J Virol.* 2004;78(7):3533-41, <http://dx.doi.org/10.1128/JVI.78.7.3533-3541.2004>.
 48. Akerman GS, Tolleson WH, Brown KL, Zyzak LL, Mourateva E, Engin TS, et al. Human papillomavirus type 16 E6 and E7 cooperate to increase epidermal growth factor receptor (EGFR) mRNA levels, overcoming mechanisms by which excessive EGFR signaling shortens the life span of normal human keratinocytes. *Cancer Res.* 2001;61(9):3837-43.
 49. Duensing S, Lee LY, Duensing A, Basile J, Piboonniyom S, Gonzalez S, et al. The human papillomavirus type 16 E6 and E7 oncoproteins cooperate to induce mitotic defects and genomic instability by uncoupling centrosome duplication from the cell division cycle. *Proc Natl Acad Sci U S A.* 2000;97(18):10002-7, <http://dx.doi.org/10.1073/pnas.170093297>.
 50. Francis DA, Schmid SI, Howley PM. Repression of the integrated papillomavirus E6/E7 promoter is required for growth suppression of cervical cancer cells. *J Virol.* 2000;74(6):2679-86, <http://dx.doi.org/10.1128/JVI.74.6.2679-2686.2000>.
 51. Nees M, Geoghegan JM, Munson P, Prabhu V, Liu Y, Androphy E, et al. Human papillomavirus type 16 E6 and E7 proteins inhibit differentiation-dependent expression of transforming growth factor-beta2 in cervical keratinocytes. *Cancer Res.* 2000;60(15):4289-98.
 52. Sherman L, Itzhaki H, Jackman A, Chen JJ, Koval D, Schlegel R. Inhibition of serum- and calcium-induced terminal differentiation of human keratinocytes by HPV 16 E6: study of the association with p53 degradation, inhibition of p53 transactivation, and binding to E6BP. *Virology.* 2002;292(2):309-20, <http://dx.doi.org/10.1006/viro.2001.1263>.
 53. Thomas JT, Laimins LA. Human papillomavirus oncoproteins E6 and E7 independently abrogate the mitotic spindle checkpoint. *J Virol.* 1998; 72(2): 1131-7.
 54. McLaughlin-Drubin ME, Münger K. The human papillomavirus E7 oncoprotein. *Virology.* 2009;384(2):335-44, <http://dx.doi.org/10.1016/j.viro.2008.10.006>.
 55. Song S, Gulliver GA, Lambert PF. Human papillomavirus type 16 E6 and E7 oncogenes abrogate radiation-induced DNA damage responses in vivo through p53-dependent and p53-independent pathways. *Proc Natl Acad Sci U S A.* 1998;95(5):2290-5, <http://dx.doi.org/10.1073/pnas.95.5.2290>.
 56. Park JW, Nickel KP, Torres AD, Lee D, Lambert PF, Kimple RJ. Human papillomavirus type 16 E7 oncoprotein causes a delay in repair of DNA damage. *Radiother Oncol.* 2014;113(3):337-44, <http://dx.doi.org/10.1016/j.radonc.2014.08.026>.
 57. Kessiss TD, Connolly DC, Hedrick L, Cho KR. Expression of HPV16 E6 or E7 increases integration of foreign DNA. *Oncogene.* 1996;13(2):427-31.
 58. Spardy N, Covella K, Cha E, Hoskins EE, Wells SI, Duensing A, et al. Human papillomavirus 16 E7 oncoprotein attenuates DNA damage checkpoint control by increasing the proteolytic turnover of claspin. *Cancer Res.* 2009;69(17):7022-9, <http://dx.doi.org/10.1158/0008-5472.CAN-09-0925>.
 59. Wallace NA, Robinson K, Howie HL, Galloway DA. HPV 5 and 8 E6 abrogate ATR activity resulting in increased persistence of UVB induced DNA damage. *PLoS Pathog.* 2012;8(7):e1002807, <http://dx.doi.org/10.1371/journal.ppat.1002807>.
 60. Zhang Y, Fan S, Meng Q, Ma Y, Katiyar P, Schlegel R, et al. BRCA1 interaction with human papillomavirus oncoproteins. *J Biol Chem.* 2005;280(39):33165-77, <http://dx.doi.org/10.1074/jbc.M505124200>.
 61. Rey O, Lee S, Park NH. Impaired nucleotide excision repair in UV-irradiated human oral keratinocytes immortalized with type 16 human papillomavirus genome. *Oncogene.* 1999;18(50):6997-7001, <http://dx.doi.org/10.1038/sj.onc.1203180>.
 62. Therrien JP, Drouin R, Baril C, Drobetsky EA. Human cells compromised for p53 function exhibit defective global and transcription-coupled nucleotide excision repair, whereas cells compromised for pRb function are defective only in global repair. *Proc Natl Acad Sci U S A.* 1999; 96(26):15038-43, <http://dx.doi.org/10.1073/pnas.96.26.15038>.
 63. Nickson CM, Moori P, Carter RJ, Rubbi CP, Parsons JL. Misregulation of DNA damage repair pathways in HPV-positive head and neck squamous cell carcinoma contributes to cellular radiosensitivity. *Oncotarget.* 2017;8(18):29963-75, <http://dx.doi.org/10.18632/oncotarget.16265>.
 64. El-Mahdy MA, Hamada FM, Wani MA, Zhu Q, Wani AA. p53-degradation by HPV-16 E6 preferentially affects the removal of cyclobutane pyrimidine dimers from non-transcribed strand and sensitizes mammary epithelial cells to UV-irradiation. *Mutat Res.* 2000;459(2):135-45, [http://dx.doi.org/10.1016/S0921-8777\(99\)00066-X](http://dx.doi.org/10.1016/S0921-8777(99)00066-X).



65. Giampieri S, Storey A. Repair of UV-induced thymine dimers is compromised in cells expressing the E6 protein from human papillomaviruses types 5 and 18. *Br J Cancer*. 2004;90(11):2203-9, <http://dx.doi.org/10.1038/sj.bjc.6601829>.
66. Shin KH, Ahn JH, Kang MK, Lim PK, Baluda MA, et al. HPV-16 E6 oncoprotein impairs the fidelity of DNA end-joining via p53-dependent and-independent pathways. *Int J Oncol*. 2006;28(1):209-15, <http://dx.doi.org/10.3892/ijo.28.1.209>.
67. Srivenugopal KS, Ali-Osman F. The DNA repair protein, O(6)-methylguanine-DNA methyltransferase is a proteolytic target for the E6 human papillomavirus oncoprotein. *Oncogene*. 2002;21(38):5940-5, <http://dx.doi.org/10.1038/sj.onc.1205762>.
68. Iftner T, Elbel M, Schopp B, Hiller T, Loizou JI, Caldecott KW, et al. Interference of papillomavirus E6 protein with single-strand break repair by interaction with XRCC1. *EMBO J*. 2002;21(17):4741-8, <http://dx.doi.org/10.1093/emboj/cdf443>.
69. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. *Cell*. 2011;144(5):646-74, <http://dx.doi.org/10.1016/j.cell.2011.02.013>.
70. Frazer IH. Interaction of human papillomaviruses with the host immune system: a well evolved relationship. *Virology*. 2009;384(2):410-4, <http://dx.doi.org/10.1016/j.virol.2008.10.004>.
71. Stanley MA, Pett MR, Coleman N. HPV: from infection to cancer. *Biochem Soc Trans*. 2007;35(Pt 6):1456-60, <http://dx.doi.org/10.1042/BST0351456>.
72. Moldovan GL, D'Andrea AD. How the fanconi anemia pathway guards the genome. *Annu Rev Genet*. 2009;43:223-49, <http://dx.doi.org/10.1146/annurev-genet-102108-134222>.
73. Spardy N, Duensing A, Charles D, Haines N, Nakahara T, Lambert PF, et al. The human papillomavirus type 16 E7 oncoprotein activates the Fanconi anemia (FA) pathway and causes accelerated chromosomal instability in FA cells. *J Virol*. 2007;81(23):13265-70, <http://dx.doi.org/10.1128/JVI.01121-07>.
74. Park JW, Pitot HC, Strati K, Spardy N, Duensing S, Grompe M, et al. Deficiencies in the Fanconi anemia DNA damage response pathway increase sensitivity to HPV-associated head and neck cancer. *Cancer Res*. 2010;70(23):9959-68, <http://dx.doi.org/10.1158/0008-5472.CAN-10-1291>.
75. Bajpai D, Banerjee A, Pathak S, Jain SK, Singh N. Decreased expression of DNA repair genes (XRCC1, ERCC1, ERCC2, and ERCC4) in squamous intraepithelial lesion and invasive squamous cell carcinoma of the cervix. *Mol Cell Biochem*. 2013;377(1-2):45-53, <http://dx.doi.org/10.1007/s11010-013-1569-y>.
76. Seiwert TY, Zuo Z, Keck MK, Khattri A, Pedamallu CS, Stricker T, et al. Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas. *Clin Cancer Res*. 2015;21(3):632-41, <http://dx.doi.org/10.1158/1078-0432.CCR-13-3310>.
77. Prati B. Expressão de genes de vias de reparo de dano ao DNA em células infectadas por papilomavírus humano (HPV). Dissertação de Mestrado. São Paulo. Depto. de Microbiologia, Instituto de Ciências Biomédicas, USP, 2014, <http://dx.doi.org/10.11606/D.42.2014.tde-12082014-175455>.
78. Boccardo E. HPV-mediated genome instability: at the roots of cervical carcinogenesis. *Cytogenet Genome Res*. 2010;128(1-3):57-65, <http://dx.doi.org/10.1159/000290657>.
79. Wei L, Gravitte PE, Song H, Maldonado AM, Ozbun MA. Nitric oxide induces early viral transcription coincident with increased DNA damage and mutation rates in human papillomavirus-infected cells. *Cancer Res*. 2009;69(11):4878-84, <http://dx.doi.org/10.1158/0008-5472.CAN-08-4695>.
80. Herdman MT, Pett MR, Roberts I, Alazawi WO, Teschendorff AE, Zhang XY, et al. Interferon-beta treatment of cervical keratinocytes naturally infected with human papillomavirus 16 episomes promotes rapid reduction in episome numbers and emergence of latent integrants. *Carcinogenesis*. 2006;27(11):2341-53, <http://dx.doi.org/10.1093/carcin/bgl172>.
81. Lace MJ, Anson JR, Haugen TH, Dierdorff JM, Turek LP. Interferon treatment of human keratinocytes harboring extrachromosomal, persistent HPV-16 plasmid genomes induces de novo viral integration. *Carcinogenesis*. 2015;36(1):151-9, <http://dx.doi.org/10.1093/carcin/bgu236>.
82. Bodily J, Laimins LA. Persistence of human papillomavirus infection: keys to malignant progression. *Trends Microbiol*. 2011;19(1):33-9, <http://dx.doi.org/10.1016/j.tim.2010.10.002>.
83. Heilman SA, Nordberg JJ, Liu Y, Sluder G, Chen JJ. Abrogation of the postmitotic checkpoint contributes to polyploidization in human papillomavirus E7-expressing cells. *J Virol*. 2009;83(6):2756-64, <http://dx.doi.org/10.1128/JVI.02149-08>.
84. Liu Y, Heilman SA, Illanes D, Sluder G, Chen JJ. p53-independent abrogation of a postmitotic checkpoint contributes to human papillomavirus E6-induced polyploidy. *Cancer Res*. 2007;67(6):2603-10, <http://dx.doi.org/10.1158/0008-5472.CAN-06-3436>.
85. Southern SA, Noya F, Meyers C, Broker TR, Chow LT, Herrington CS. Tetrasomy is induced by human papillomavirus type 18 E7 gene expression in keratinocyte raft cultures. *Cancer Res*. 2001;61(12):4858-63.
86. Duensing A, Spardy N, Chatterjee P, Zheng L, Parry J, Cuevas R, et al. Centrosome overduplication, chromosomal instability, and human papillomavirus oncoproteins. *Environ Mol Mutagen*. 2009;50(8):741-7, <http://dx.doi.org/10.1002/em.20478>.
87. Nguyen CL, McLaughlin-Drubin ME, Mürger K. Delocalization of the microtubule motor Dynein from mitotic spindles by the human papillomavirus E7 oncoprotein is not sufficient for induction of multipolar mitoses. *Cancer Res*. 2008;68(21):8715-22, <http://dx.doi.org/10.1158/0008-5472.CAN-08-1303>.
88. Duensing S, Mürger K. Centrosome abnormalities, genomic instability and carcinogenic progression. *Biochim Biophys Acta*. 2001;1471(2):M81-8, [http://dx.doi.org/10.1016/S0304-419X\(00\)00025-1](http://dx.doi.org/10.1016/S0304-419X(00)00025-1).
89. Alazawi W, Pett M, Strauss S, Moseley R, Gray J, Stanley M, et al. Genomic imbalances in 70 snap-frozen cervical squamous intraepithelial lesions: associations with lesion grade, state of the HPV16 E2 gene and clinical outcome. *Br J Cancer*. 2004;91(12):2063-70, <http://dx.doi.org/10.1038/sj.bjc.6602237>.
90. Stanley MA, Browne HM, Appleby M, Minson AC. Properties of a non tumorigenic human cervical keratinocyte cell line. *Int J Cancer*. 1989;43(4):672-6, <http://dx.doi.org/10.1002/ijc.2910430422>.
91. Méhes G, Speich N, Bollmann M, Bollmann R. Chromosomal aberrations accumulate in polyploid cells of high-grade squamous intraepithelial lesions (HSIL). *Pathol Oncol Res*. 2004;10(3):142-8, <http://dx.doi.org/10.1007/BF03033742>.
92. Rihet S, Lorenzato M, Clavel C. Oncogenic human papillomaviruses and ploidy in cervical lesions. *J Clin Pathol*. 1996;49(11):892-6, <http://dx.doi.org/10.1136/jcp.49.11.892>.
93. Pett MR, Alazawi WO, Roberts I, Dowen S, Smith DI, Stanley MA, et al. Acquisition of high-level chromosomal instability is associated with integration of human papillomavirus type 16 in cervical keratinocytes. *Cancer Res*. 2004;64(4):1359-68, <http://dx.doi.org/10.1158/0008-5472.CAN-03-3214>.
94. Arias-Pulido H, Narayan G, Vargas H, Mansukhani M, Murty VV. Mapping common deleted regions on 5p15 in cervical carcinoma and their occurrence in precancerous lesions. *Mol Cancer*. 2002;1:3, <http://dx.doi.org/10.1186/1476-4598-1-3>.
95. Rao PH, Arias-Pulido H, Lu XY, Harris CP, Vargas H, Zhang FF, et al. Chromosomal amplifications, 3q gain and deletions of 2q33-q37 are the frequent genetic changes in cervical carcinoma. *BMC Cancer*. 2004;4:5, <http://dx.doi.org/10.1186/1471-2407-4-5>.
96. Sokolova I, Algeciras-Schimmich A, Song M, Sitalo S, Policht F, Kipp BR, et al. Chromosomal biomarkers for detection of human papillomavirus associated genomic instability in epithelial cells of cervical cytology specimens. *J Mol Diagn*. 2007;9(5):604-11, <http://dx.doi.org/10.2353/jmolx.2007.070007>.
97. Wilting SM, Smeets SJ, Snijders PJ, van Wieringen WN, van de Wiel MA, Meijer GA, et al. Genomic profiling identifies common HPV-associated chromosomal alterations in squamous cell carcinomas of cervix and head and neck. *BMC Med Genomics*. 2009;2:32, <http://dx.doi.org/10.1186/1755-8794-2-32>.
98. Wistuba II, Montellano FD, Milchgrub S, Virmani AK, Behrens C, Chen H, et al. Deletions of chromosome 3p are frequent and early events in the pathogenesis of uterine cervical carcinoma. *Cancer Res*. 1997;57(15):3154-8.
99. Cattani P, Hohauser S, Bellacosa A, Genuardi M, Cavallo S, Rovella V, et al. Association between cyclin D1 (CCND1) gene amplification and human papillomavirus infection in human laryngeal squamous cell carcinoma. *Clin Cancer Res*. 1998;4(11):2585-9.
100. Gagne SE, Jensen R, Polvi A, Da Costa M, Ginzinger D, Efird JT, et al. High-resolution analysis of genomic alterations and human papillomavirus integration in anal intraepithelial neoplasia. *J Acquir Immune Defic Syndr*. 2005;40(2):182-9, <http://dx.doi.org/10.1097/01.qai.0000179460.61987.33>.
101. Steenbergen RD, Hermesen MA, Walboomers JM, Joenje H, Arwert F, Meijer CJ, et al. Integrated human papillomavirus type 16 and loss of heterozygosity at 11q22 and 18q21 in an oral carcinoma and its derivative cell line. *Cancer Res*. 1995;55(22):5465-71.
102. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. *Cell*. 1990;63(6):1129-36, [http://dx.doi.org/10.1016/0092-8674\(90\)90409-8](http://dx.doi.org/10.1016/0092-8674(90)90409-8).
103. Mürger K, Phelps WC, Bubbs V, Howley PM, Schlegel R. The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes. *J Virol*. 1989;63(10):4417-21.
104. Boyer SN, Wazer DE, Band V. E7 protein of human papilloma virus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway. *Cancer Res*. 1996;56(20):4620-4.
105. Tommasino M, Accardi R, Caldeira S, Dong W, Malanchi I, Smet A, et al. The role of TP53 in Cervical carcinogenesis. *Hum Mutat*. 2003;21(3):307-12, <http://dx.doi.org/10.1002/humu.10178>.
106. Hong A, Zhang X, Jones D, Veillard AS, Zhang M, Martin A, et al. Relationships between p53 mutation, HPV status and outcome in oropharyngeal squamous cell carcinoma. *Radiother Oncol*. 2016;118(2):342-9, <http://dx.doi.org/10.1016/j.radonc.2016.02.009>.
107. Butz K, Whitaker N, Denk C, Ullmann A, Geisen C, Hoppe-Seyler F. Induction of the p53-target gene GADD45 in HPV-positive cancer cells. *Oncogene*. 1999;18(14):2381-6, <http://dx.doi.org/10.1038/sj.onc.1202557>.



108. Butz K, Geisen C, Ullmann A, Spitkovsky D, Hoppe-Seyler F. Cellular responses of HPV-positive cancer cells to genotoxic anti-cancer agents: repression of E6/E7-oncogene expression and induction of apoptosis. *Int J Cancer*. 1996;68(4):506-13, [http://dx.doi.org/10.1002/\(SICI\)1097-0215\(19961115\)68:4<506::AID-IJC17>3.0.CO;2-2](http://dx.doi.org/10.1002/(SICI)1097-0215(19961115)68:4<506::AID-IJC17>3.0.CO;2-2).
109. Butz K, Shahabeddin L, Geisen C, Spitkovsky D, Ullmann A, Hoppe-Seyler F. Functional p53 protein in human papillomavirus-positive cancer cells. *Oncogene*. 1995;10(5):927-36.
110. Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tân PF, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. *N Engl J Med*. 2010 Jul 1;363(1):24-35, <http://dx.doi.org/10.1056/NEJMoa0912217>.
111. Monk BJ, Sill MW, Burger RA, Gray HJ, Buekers TE, Roman LD. Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study. *J Clin Oncol*. 2009;27(7):1069-74, <http://dx.doi.org/10.1200/JCO.2008.18.9043>.
112. Zigelboim I, Wright JD, Gao F, Case AS, Massad LS, Mutch DG, et al. Multicenter phase II trial of topotecan, cisplatin and bevacizumab for recurrent or persistent cervical cancer. *Gynecol Oncol*. 2013;130(1):64-8, <http://dx.doi.org/10.1016/j.ygyno.2013.04.009>.
113. Reinhardt HC, Jiang H, Hemann MT, Yaffe MB. Exploiting synthetic lethal interactions for targeted cancer therapy. *Cell Cycle*. 2009;8(19):3112-9, <http://dx.doi.org/10.4161/cc.8.19.9626>.
114. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. *Nature*. 2005;434(7035):913-7, <http://dx.doi.org/10.1038/nature03443>.
115. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. *Nature*. 2005;434(7035):917-21, <http://dx.doi.org/10.1038/nature03445>.
116. Rouleau M, Patel A, Hendzel MJ, Kaufmann SH, Poirier GG. PARP inhibition: PARP1 and beyond. *Nat Rev Cancer*. 2010;10(4):293-301, <http://dx.doi.org/10.1038/nrc2812>.
117. Lin KY, Kraus WL. PARP Inhibitors for Cancer Therapy. *Cell*. 2017;169(2):183, <http://dx.doi.org/10.1016/j.cell.2017.03.034>.
118. Schreiber V, Dantzer F, Ame JC, de Murcia G. Poly(ADP-ribose): novel functions for an old molecule. *Nat Rev Mol Cell Biol*. 2006;7(7):517-28, <http://dx.doi.org/10.1038/nrm1963>.
119. Murai J, Huang SY, Das BB, Renaud A, Zhang Y, Doroshow JH, et al. Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors. *Cancer Res*. 2012;72(21):5588-99, <http://dx.doi.org/10.1158/0008-5472.CAN-12-2753>.
120. Konstantinopoulos PA, Ceccaldi R, Shapiro GI, D'Andrea AD. Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer. *Cancer Discov*. 2015;5(11):1137-54, <http://dx.doi.org/10.1158/2159-8290.CD-15-0714>.
121. Scott CL, Swisher EM, Kaufmann SH. Poly (ADP-ribose) polymerase inhibitors: recent advances and future development. *J Clin Oncol*. 2015;33(12):1397-406, <http://dx.doi.org/10.1200/JCO.2014.58.8848>.
122. Ljungman M. Targeting the DNA damage response in cancer. *Chem Rev*. 2009;109(7):2929-50, <http://dx.doi.org/10.1021/cr900047g>.
123. Mirghani H, Amen F, Tao Y, Deutsch E, Levy A. Increased radiosensitivity of HPV-positive head and neck cancers: Molecular basis and therapeutic perspectives. *Cancer Treat Rev*. 2015;41(10):844-52, <http://dx.doi.org/10.1016/j.ctrv.2015.10.001>.
124. Rieckmann T, Tribius S, Grob TJ, Meyer F, Busch CJ, Petersen C, et al. HNSCC cell lines positive for HPV and p16 possess higher cellular radiosensitivity due to an impaired DSB repair capacity. *Radiother Oncol*. 2013;107(2):242-6, <http://dx.doi.org/10.1016/j.radonc.2013.03.013>.